14 / 31
Cabozantinib en 1L: Cabosun
Characteristic
Cabozantinib (n=79)
Sunitinib (n=78)
Median age, years (range)
63 (56–69)
64 (57–71)
Male, %
84
73
ECOG performance status, %
0/1/2
46/42/13
46/41/13
IMDC risk group,
a
%
Intermediate/poor
81/19
81/19
Prior nephrectomy, %
72
77
Bone metastases, %
37
36
Positive MET status,
b
%
41
38
No. metastatic sites per investigator, %
1/2/≥3
22/47/32
33/26/41
Metastatic sites per investigator, %
Nodal
57
54
Lung
70
69
Liver
19
26
Bone
39
38
CNS/brain
4
3
Características de los pacientes